CN116761615A - 抗病毒剂 - Google Patents

抗病毒剂 Download PDF

Info

Publication number
CN116761615A
CN116761615A CN202280010804.2A CN202280010804A CN116761615A CN 116761615 A CN116761615 A CN 116761615A CN 202280010804 A CN202280010804 A CN 202280010804A CN 116761615 A CN116761615 A CN 116761615A
Authority
CN
China
Prior art keywords
strain
carbons
antiviral agent
hydrogen atom
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280010804.2A
Other languages
English (en)
Chinese (zh)
Inventor
前仲胜実
松田彰
泽洋文
大场靖子
佐佐木道仁
上村健太朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Original Assignee
Hokkaido University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC filed Critical Hokkaido University NUC
Publication of CN116761615A publication Critical patent/CN116761615A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280010804.2A 2021-01-20 2022-01-20 抗病毒剂 Pending CN116761615A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-007531 2021-01-20
JP2021007531 2021-01-20
PCT/JP2022/001997 WO2022158528A1 (ja) 2021-01-20 2022-01-20 抗ウイルス剤

Publications (1)

Publication Number Publication Date
CN116761615A true CN116761615A (zh) 2023-09-15

Family

ID=82549509

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280010804.2A Pending CN116761615A (zh) 2021-01-20 2022-01-20 抗病毒剂

Country Status (8)

Country Link
US (1) US20240131046A1 (https=)
EP (1) EP4282420A4 (https=)
JP (1) JPWO2022158528A1 (https=)
KR (1) KR20230137361A (https=)
CN (1) CN116761615A (https=)
AU (1) AU2022210132A1 (https=)
CA (1) CA3206486A1 (https=)
WO (1) WO2022158528A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820248A (zh) * 2021-04-14 2024-04-05 盐野义制药株式会社 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN116782904A (zh) * 2021-09-28 2023-09-19 盐野义制药株式会社 含有三嗪衍生物的医药组合物
CA3233206A1 (en) * 2021-09-28 2023-04-06 Yuki Tachibana Pharmaceutical composition containing triazine derivative
TW202320793A (zh) * 2021-09-28 2023-06-01 日商塩野義製藥股份有限公司 含有三嗪衍生物之醫藥組合物
JP7253866B1 (ja) * 2021-11-24 2023-04-07 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤
WO2023054732A2 (ja) * 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
WO2024076951A2 (en) * 2022-10-04 2024-04-11 The Scripps Research Institute Antiviral prodrugs and formulations thereof
JPWO2024075794A1 (https=) * 2022-10-04 2024-04-11
CN117357531A (zh) * 2023-09-08 2024-01-09 湖北九康通生物医药有限公司 一种药物组合物、其制备方法和其应用
CN117417387A (zh) * 2023-09-13 2024-01-19 苏州翔实医药发展有限公司 一种核苷类似物的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021198115A1 (en) * 2020-04-01 2021-10-07 UNION therapeutics A/S Treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US11738025B2 (en) * 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
KR20210151949A (ko) * 2020-04-05 2021-12-14 화이자 인코포레이티드 Covid-19의 치료를 위한 화합물 및 방법
IL297319A (en) * 2020-04-13 2022-12-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Use of metabolic regulators for the treatment of covid-19
EP3930730A4 (en) * 2020-04-15 2022-05-11 Starpharma Pty Limited PROPHYLAXIS FOR CORONAVIRUS AND/OR RESPIRATORY SYNCYTIAL VIRUS INFECTION
EP3912628A1 (en) * 2020-05-20 2021-11-24 Institut de Recherche en Semiochimie et Ethologie Appliquée Nucleoside analogues to inhibit the main protease of a coronavirus
US20220177982A1 (en) * 2020-12-03 2022-06-09 Regeneron Pharmaceuticals, Inc. Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment Thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021198115A1 (en) * 2020-04-01 2021-10-07 UNION therapeutics A/S Treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEKMAN ET AL.: "Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2", MOLECULAR CELL, vol. 80, 17 December 2020 (2020-12-17), pages 1104 *
XUEWU ZHANG等: "Generation of predictive pharmacophore model for SARS-coronavirus main proteinase", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 2005, 5 November 2004 (2004-11-05), pages 57 - 62 *

Also Published As

Publication number Publication date
AU2022210132A1 (en) 2023-08-31
CA3206486A1 (en) 2022-07-28
KR20230137361A (ko) 2023-10-04
WO2022158528A1 (ja) 2022-07-28
EP4282420A1 (en) 2023-11-29
JPWO2022158528A1 (https=) 2022-07-28
EP4282420A4 (en) 2024-11-27
US20240131046A1 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
CN116761615A (zh) 抗病毒剂
JP2024003097A (ja) コロナウイルス感染の治療におけるファビピラビルの使用
KR102952809B1 (ko) 뉴클레오티드계 화합물의 코로나 바이러스 감염증의 치료에의 사용
IL217228A (en) Compounds of Type 2'-Deoxy-2'-Fluoro-2'-c-Methyluridine Nucleoside Phosphoramide Compounds
CN115768418B (zh) 病毒抑制
Huang et al. GS-441524 inhibits African swine fever virus infection in vitro
IL237119A (en) Heterocyclic carboxamides for the treatment of viral diseases
WO2017223178A1 (en) Treating viral infections with impdh inhibitors
AU2022284147A1 (en) Use of 5-nitro-8-hydroxyquinoline
CN117320748A (zh) Covid-19进入抑制剂对covid-19复制的遏制
HK40104268A (en) Anti-viral agent
CN114762694B (zh) 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用
AU2024348542A1 (en) Oligonucleotide compositions and methods thereof
Li et al. Dihydroartemisinin inhibits Micropterus salmoides rhabdovirus infection in vitro and in vivo
US20230241037A1 (en) Cross-linked medication for treatment of coronaviral infection and method of treatment
CN101772347A (zh) 正义单链RNA包膜病毒的2-氨基-2,7-双脱氧-α-D-甘油-D-葡糖-吡喃庚糖基抑制剂
EP4431100A1 (en) Antiviral agent
JP2023072634A (ja) 抗ウイルス剤
EP4262793B1 (en) Pharmaceutical combination product comprising a protoparvovirus and an antiviral benzimidazole and uses thereof for treating cancer
KR100930480B1 (ko) 신규 디아릴 헵타노이드계 화합물 및 그 용도
BR112020008714A2 (pt) uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus
CN111329858B (zh) 一种小分子抑制剂在抑制病毒沉默抑制蛋白中的应用
US20250345307A1 (en) Synthetic rocaglates with broad-spectrum antiviral activities and uses thereof
JP2024064068A (ja) ウイルス増殖阻害剤
KR100931249B1 (ko) 신규 디아릴 헵타노이드계 화합물 및 그 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination